Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Assets (2023 - 2025)

Kura Oncology (KURA) has disclosed Non-Current Assets for 3 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 93.74% to $29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $100.3 million, a 60.79% increase, with the full-year FY2025 number at $29.7 million, up 93.74% from a year prior.
  • Non-Current Assets was $29.7 million for Q4 2025 at Kura Oncology, up from $28.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $29.7 million in Q4 2025 to a low of $9.1 million in Q2 2023.
  • A 3-year average of $17.6 million and a median of $15.9 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: fell 6.83% in 2024, then soared 93.74% in 2025.
  • Kura Oncology's Non-Current Assets stood at $16.5 million in 2023, then fell by 6.83% to $15.3 million in 2024, then skyrocketed by 93.74% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Non-Current Assets are $29.7 million (Q4 2025), $28.7 million (Q3 2025), and $22.3 million (Q2 2025).